Finland· FI-REL-REL7360
Neo-Peni-Sulfa Vet
A bentsyylipenisilliini, yhdistelmävalmisteet muiden bakteerilääkkeiden kanssa product, registered in Finland by Orion Corporation Orion Pharma.
Checked against Fimea (Finland) on
Informational only — not a medical device.
The record
At a glance
Fimea (Finland)- Manufacturer
- Orion Corporation Orion Pharma
- Country
- Finland (FI)
- ATC code
- QJ51RC22
- ATC class
- Bentsyylipenisilliini, yhdistelmävalmisteet muiden bakteerilääkkeiden kanssa
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under QJ51RC22
Bentsyylipenisilliini, yhdistelmävalmisteet muiden bakteerilääkkeiden kanssa, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d911ad87-f4d9-4bfa-865e-899f1e46cef0 GET /v1/drugs/d911ad87-f4d9-4bfa-865e-899f1e46cef0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "intramammaari",
"route": null,
"ddd_unit": null,
"strength": null,
"atc_label": "Bentsyylipenisilliini, yhdistelmävalmisteet muiden bakteerilääkkeiden kanssa",
"ma_number": "4426",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL7360",
"authorised_at": "1966-12-28"
}See everything about Neo-Peni-Sulfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.